{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:03:20Z","timestamp":1793437400234,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40258-023-00807-7","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T19:01:58Z","timestamp":1683918118000},"page":"661-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost\u2011Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)\u2011Positive Non\u2011Small\u2011Cell Lung Cancer in Sweden"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6581-350X","authenticated-orcid":false,"given":"Jaesh","family":"Naik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Beavers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1905-4047","authenticated-orcid":false,"given":"Fredrik O. L.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2379-6094","authenticated-orcid":false,"given":"Laura","family":"Iadeluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissy","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"807_CR1","unstructured":"American Cancer Society. What is lung cancer? 2019. Updated 1 Oct 2019. Available at: https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/what-is.html. Accessed 4 Sep 2020."},{"key":"807_CR2","unstructured":"Statista. Number of new cases of lung cancer in Sweden from 2010 to 2020. 2022. Available at: https:\/\/www.statista.com\/statistics\/891980\/number-of-lung-cancer-cases-in-sweden\/. Accessed 5 Apr 2022."},{"key":"807_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3410\/m3-21","volume":"3","author":"B Hallberg","year":"2011","unstructured":"Hallberg B, Palmer RH. ALK and NSCLC: targeted therapy with ALK inhibitors. F1000 Med Rep. 2011;3:21. https:\/\/doi.org\/10.3410\/m3-21.","journal-title":"F1000 Med Rep"},{"issue":"5","key":"807_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4065\/83.5.584","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584\u201394. https:\/\/doi.org\/10.4065\/83.5.584.","journal-title":"Mayo Clin Proc"},{"issue":"7153","key":"807_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136. https:\/\/doi.org\/10.1038\/nature05945.","journal-title":"Nature"},{"key":"807_CR6","unstructured":"Socialstyrelsen National Board of Health and Welfare. Cancer registry, statistics and data. Available at: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/cancerregistret\/. Accessed 14 Jun 2022."},{"key":"807_CR7","unstructured":"National Lung Cancer Register. 2022. Available at: https:\/\/statistik.incanet.se\/Lunga\/3"},{"key":"807_CR8","unstructured":"Regionalt Cancercentrum. Lungcancer Nationellt v\u00e5rdprogram. Lungcancer Nationellt v\u00e5rdprogram, 2022-05-10 Version 6.0. 2020. Available at: https:\/\/www.cancercentrum.se\/globalassets\/cancerdiagnoser\/lunga-och-lungsack\/vardprogram\/nationellt-vardprogram-lungcancer.pdf. Accessed 13 Jun 2022."},{"issue":"9","key":"807_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"issue":"10072","key":"807_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"J-C Soria","year":"2017","unstructured":"Soria J-C, Tan DS, Chiari R, Wu Y-L, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 2017;389(10072):917\u201329.","journal-title":"The Lancet"},{"key":"807_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00063","author":"JF Gainor","year":"2017","unstructured":"Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/po.17.00063.","journal-title":"JCO Precis Oncol"},{"key":"807_CR12","unstructured":"ESMO. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Available at: https:\/\/www.esmo.org\/content\/download\/347819\/6934778\/1\/ESMO-CPG-mNSCLC-15SEPT2020.pdf. Accessed 13 Jun 2022."},{"key":"807_CR13","unstructured":"National Prescribed Drug Register. Register of Medicinal Products. 2022. Available at: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/lakemedelsregistret\/. Accessed 13 Jun 2022."},{"key":"807_CR14","unstructured":"European Medicines Agency (EMA). Summary of opinion (initial authorisation) Lorviqua (lorlatinib). 2019. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-lorviqua_en.pdf. Accessed 13 Jun 2022."},{"key":"807_CR15","unstructured":"Tandv\u00e5rds-och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Lorviqua is included in the high-cost protection with limitation. 2019. Available at: https:\/\/www.tlv.se\/beslut\/beslut-lakemedel\/begransad-subvention\/arkiv\/2019-09-30-lorviqua-ingar-i-hogkostnadsskyddet-med-begransning.html. Accessed 13 Jun 2022."},{"key":"807_CR16","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Application within the pharmaceutical benefits. 2022. Available at: https:\/\/www.tlv.se\/download\/18.66b0fb1f17f96a8babdb5c46\/1648480312859\/bes220324_lorviqua_3992-2021.pdf. Accessed 13 Jun 2022."},{"issue":"21","key":"807_CR17","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2027187.","journal-title":"N Engl J Med"},{"key":"807_CR18","unstructured":"Tandv\u00e5rds-och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Application within the pharmaceutical benefits. 2018. Available at: https:\/\/www.tlv.se\/download\/18.577a4290162f616250871891\/1524726796321\/bes180420_alecensa.pdf. Accessed 13 Jun 2022."},{"key":"807_CR19","unstructured":"National Institute for Health and Care Excellence (NICE). Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536). 2018. Available at: https:\/\/www.nice.org.uk\/guidance\/ta536. Accessed 29 Mar 2021."},{"key":"807_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (TA670). 2021. Available at: https:\/\/www.nice.org.uk\/guidance\/ta670. Accessed 14 Jan 2021."},{"key":"807_CR21","unstructured":"National Institute for Health and Care Excellence (NICE). Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500). 2018. Available at: https:\/\/www.nice.org.uk\/guidance\/ta500. Accessed 17 Jan 2023."},{"key":"807_CR22","unstructured":"National Institute for Health and Care Excellence (NICE). Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406). 2016. Available at: https:\/\/www.nice.org.uk\/guidance\/ta406. Accessed 17 Jan 2023."},{"key":"807_CR23","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Amendment to the Dental and Pharmaceutical Benefits Agency's general advice (TLVAR 2003:2) on economic evaluations. 2017. Available at: https:\/\/www.tlv.se\/download\/18.467926b615d084471ac3230c\/1510316374332\/TLVAR_2017_1.pdf. Accessed 13 Jun 2022."},{"issue":"21","key":"807_CR24","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Lee J-S, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. New Eng J Med. 2018;379(21):2027\u201339.","journal-title":"New Eng J Med"},{"issue":"5","key":"807_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","volume":"7","author":"C Zhou","year":"2019","unstructured":"Zhou C, Kim S-W, Reungwetwattana T, Zhou J, Zhang Y, He J, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019;7(5):437\u201346.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"807_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","volume":"13","author":"Y-L Wu","year":"2018","unstructured":"Wu Y-L, Lu S, Lu Y, Zhou J, Shi Y-K, Sriuranpong V, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in east asian patients with ALK-Positive advanced non-small cell lung Cancer. J Thoracic Oncol. 2018;13(10):1539\u201348.","journal-title":"J Thoracic Oncol"},{"issue":"10089","key":"807_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. The Lancet. 2017;390(10089):29\u201339.","journal-title":"The Lancet"},{"issue":"8","key":"807_CR28","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056\u201364. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.478.","journal-title":"Ann Oncol"},{"key":"807_CR29","unstructured":"European Medicines Agency (EMA). Alecensa. 2021. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alecensa. Accessed 13 Jun 2022."},{"key":"807_CR30","unstructured":"European Medicines Agency (EMA). Alunbrig (Brigatinib). 2022. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alunbrig. Accessed 14 Jun 2022."},{"key":"807_CR31","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual 2022. 2022. Available at: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"},{"issue":"5","key":"807_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B Van Hout","year":"2012","unstructured":"Van Hout B, Janssen M, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health."},{"issue":"8","key":"807_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40273-020-00905-7","volume":"38","author":"K Burstr\u00f6m","year":"2020","unstructured":"Burstr\u00f6m K, Teni FS, Gerdtham UG, Leidl R, Helgesson G, Rolfson O, et al. Experience-based Swedish TTO and VAS value sets for EQ-5D-5L health states. Pharmacoeconomics. 2020;38(8):839\u201356. https:\/\/doi.org\/10.1007\/s40273-020-00905-7.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"807_CR34","doi-asserted-by":"publisher","first-page":"A650","DOI":"10.1016\/j.jval.2014.08.2364","volume":"17","author":"A Roughley","year":"2014","unstructured":"Roughley A, Damonte E, Taylor-Stokes G, Rider A, Munk VC. Impact of brain metastases on quality of life and estimated life expectancy in patients with advanced non-small cell lung cancer. Value Health. 2014;17(7):A650. https:\/\/doi.org\/10.1016\/j.jval.2014.08.2364.","journal-title":"Value Health"},{"issue":"5","key":"807_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00700.x.","journal-title":"Value Health."},{"key":"807_CR36","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Search the database. Available at: https:\/\/www.tlv.se\/beslut\/sok-i-databasen.html. Accessed 13 Jun 2022."},{"key":"807_CR37","unstructured":"Electronic Medicines Compendium (eMC). Summary of Product Characteristics: Alecensa. 2021. Updated 17 April 2020. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/2438\/smpc#gref. Accessed 18 Mar 2021."},{"key":"807_CR38","unstructured":"Electronic Medicines Compendium (eMC). Summary of Product Characteristics: Xalkori. 2021. Updated 9 October 2020. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/2857\/smpc#gref. Accessed 18 Mar 2021."},{"key":"807_CR39","unstructured":"Electronic Medicines Compendium (eMC). Summary of Product Characteristics: Lorviqua. 2021. Updated 28 September 2021. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/10632#gref. Accessed 8 Apr 2022."},{"key":"807_CR40","unstructured":"Southern Healthcare Region. Regional prices and reimbursements for the Southern Health Care Region 2021. 2021. Available at: https:\/\/sodrasjukvardsregionen.se\/download\/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2021\/. Accessed 13 Jun 2022."},{"key":"807_CR41","unstructured":"Statistics Sweden (SCB). Basic tables LFS, aged 15-74, annual average according to international definition. Updated 25 May 2022. Available at: https:\/\/www.scb.se\/hitta-statistik\/statistik-efter-amne\/arbetsmarknad\/arbetskraftsundersokningar\/arbetskraftsundersokningarna-aku\/pong\/tabell-och-diagram\/icke-sasongrensade-data\/grundtabeller-aku-1574-ar-ar\/. Accessed 13 Jun 2022."},{"issue":"8","key":"807_CR42","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40273-021-01015-8","volume":"39","author":"FOL Nilsson","year":"2021","unstructured":"Nilsson FOL, Asanin ST, Masters ET, Iadeluca L, Almond C, Cooper M, et al. The cost-effectiveness of lorlatinib versus chemotherapy as a second- or third-line treatment in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in Sweden. Pharmacoeconomics. 2021;39(8):941\u201352. https:\/\/doi.org\/10.1007\/s40273-021-01015-8.","journal-title":"Pharmacoeconomics"},{"key":"807_CR43","unstructured":"Skatteverket. Employer's contributions. Available at: https:\/\/www.skatteverket.se\/foretagochorganisationer\/arbetsgivare\/arbetsgivaravgifterochskatteavdrag\/arbetsgivaravgifter.4.233f91f71260075abe8800020817.html. Accessed 14 Jun 2022."},{"key":"807_CR44","unstructured":"Statistics Sweden (SCB). Average monthly salary, SEK by sector, occupation (SSYK 2012), sex, level of education and year. 2021. Available at: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__AM__AM0110\/. Accessed 13 Jun 2022."},{"issue":"4","key":"807_CR45","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"807_CR46","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","volume":"33","author":"M Svensson","year":"2015","unstructured":"Svensson M, Nilsson FO, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33(11):1229\u201336. https:\/\/doi.org\/10.1007\/s40273-015-0307-6.","journal-title":"Pharmacoeconomics"},{"key":"807_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684073","volume":"11","author":"S Li","year":"2021","unstructured":"Li S, Li J, Peng L, Li Y, Wan X. Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Front Oncol. 2021;11: 684073. https:\/\/doi.org\/10.3389\/fonc.2021.684073.","journal-title":"Front Oncol"},{"key":"807_CR48","first-page":"DX44","volume":"113","author":"M Svensson","year":"2016","unstructured":"Svensson M, Nilsson F. The Swedish Dental and Pharmaceutical Benefits Agency\u2019s willingness to pay for new drugs has been analyzed [in Swedish]. Lakartidningen. 2016;113:DX44.","journal-title":"Lakartidningen"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00807-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-023-00807-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-023-00807-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T09:08:07Z","timestamp":1685524087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-023-00807-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s40258-023-00807-7","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"26 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fredrik O.L. Nilsson is an employee of Pfizer AB, Sweden, and owns stock in Pfizer Inc. At the time this study was conducted, Laura Iadeluca was an employee of Pfizer Inc, and owns stock in Pfizer Inc. Chrissy Lowry and Norma Beavers are employees of Lumanity, which was a paid consultant to Pfizer in connection with the development of this manuscript. At the time this study was conducted, Jaesh Naik was an employee of Lumanity, which was a paid consultant to Pfizer in connection with the development of this manuscript. The authors did not receive direct payment as a result of this work outside of their normal salary payments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Data are contained within the article and its electronic supplementary material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication from Patients\/Participants"}},{"value":"Available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This manuscript was written and edited by Jaesh Naik, Norma Beavers, Fredrik O.L. Nilsson, Laura Iadeluca and Chrissy Lowry. The global cost-effectiveness model was developed by Jaesh Naik and Matthew Massello. Figures and tables were designed by Jaesh Naik and Chrissy Lowry. All authors approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}